KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders (QoQ) (2014 - 2025)
KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders (QoQ) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -15.13% |
| Oct 31, 2024 | -28.72% |
| Jul 31, 2024 | -237.87% |
| Apr 30, 2024 | 201.05% |
| Jan 31, 2024 | 25.52% |
| Oct 31, 2023 | -0.36% |
| Jul 31, 2023 | -28.16% |
| Apr 30, 2023 | 18.98% |
| Jan 31, 2023 | -0.48% |
| Oct 31, 2022 | 2.33% |
| Jul 31, 2022 | 33.55% |
| Apr 30, 2022 | -51.51% |
| Jan 31, 2022 | -13.51% |
| Oct 31, 2021 | -50.95% |
| Jul 31, 2021 | -14.09% |
| Apr 30, 2021 | -48.35% |
| Jan 31, 2021 | 1.70% |
| Oct 31, 2020 | 10.14% |
| Jul 31, 2020 | -96.40% |
| Apr 30, 2020 | 48.16% |